Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis

Critical Care Medicine

Volumn 34, Issue 1, 2006, Pages E188-

  Bluth, Martin H ^a,c   Kandil, Emad ^a   Mueller, Catherine M ^a   Shah, Vishal ^b   Lin, Yin Yao ^a   Zhang, Hong ^a   Dresner, Lisa ^a   Lempert, Leonid ^a   Nowakowski, Maja ^a   Gross, Richard ^b   Schulze, Robert ^a   Zenilman, Michael E ^a  

^a SUNY Downstate Medical Center   (United States)

^b POLYTECHNIC UNIVERSITY   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Cytokines; Glycolipid; Lipopolysaccharide; Mortality; Nitric oxide; Sepsis; Sophorolipid

Indexed keywords

DIMETHYL SULFOXIDE; GLYCOLIPID; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; SOPHOROLIPID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; LABORATORY TEST; LYMPHOCYTE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; SEPTIC SHOCK;

EID: 29744447062     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000196212.56885.50     Document Type: Article

References (71)

1. Balk RA: Severe sepsis and septic shock: Definitions, epidemiology and clinical manifestations. Critical Care Clinics 2000; 16:179-192
2. Bone RC: Pathogenesis of sepsis. Ann Intern Med 1991; 115:457-469
3. Platz J, Beisswenger C, Dalpke A, et al: Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol 2004; 173:1219-1223
4. Sparwasser T, Miethke T, Lipford G, et al: Macrophages sense pathogens via DNA motifs: Induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol 1997; 27:1671-1679
5. Cowdery JS, Chace JH, Yi AK, et al: Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996; 156:4570-4575
6. Bone RC, Grodzin CJ, Balk RA: Sepsis: A new hypothesis for the pathogenesis of the disease process. Chest 1997; 112:235-243
7. Liaw PCY, Esmon CT, Kahnamoui K, et al: Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004; 104:3958-3964
8. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS): A prospective study. JAMA 1995; 273:117-123
9. Cohen J, McConnell JS: Antibiotic-induced endotoxin release. Lancet 1985; 2:1069-1070
10. Gorin APJ, Spencer JFT, Tulloch AP: Hydroxy fatty acid glycosides of sophorose from Torulopsis magnoliae. Can J Chem 1961; 39:846-895
11. Davila AM, Marchai R, Vandecasteele JP: Kinetics and balance of fermentation free from product inhibition: sophorose lipid production by Candida bombicola. Appl Microbiol Biotech, 1992; 38:6-11
12. Isoda H, Kitamoto D, Shinmoto H, et al: Microbial extracellular glycolipid induction of differentiation and inhibition of the protein kinase C activity of human promyelocytic leukemia cell line HL60. Biosci Biotechnol Biochem 1997; 61:609-614
13. Yang D, Satoh M, Udea H, et al: Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 1994; 38:287-293
14. Kumazawa E, Akimoto T, Kita Y, et al: Intra-tumoral production of tumor necrosis factor augmented by endogenous interferons results in potent antitumor effects of DT-5461, a synthetic lipid A analog. J Immunother Emphasis Tumor Immunol 1995; 17:141-150
15. Akimoto T, Kumazawa E, Jimbo T, et al: Antitumor effect of DT-5461a, a synthetic low-toxicity lipid A analog, involves endogenous tumor necrosis factor induction subsequent to macrophage activation. Int J Immunopharmacol 1994; 16,:887-893
16. Nguyen NM, Lehr JE, Shelly CI, et al: The effect of maltose tetrapalmitate (MTP) on prostate cancer growth in vivo and in vitro. Anticancer Res 1993; 13:2053-2058
17. Van Kaer L: Alpha-galactosylceramide therapy for autoimmune disease: Prospects and obstacles. Nat Rev Immunol 2005; 5:31-42
18. Kawata T, Bristol JR, Rose JR, et al: Anti-endotoxin activity of a novel synthetic lipid A analog Prog Clin Biol Res 1995; 392:499-509
19. Kiani A, Tschiersch A, Gaboriau E, et al: Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood 1997; 90:1673-1683
20. Schutze E, Hildebrandt J, Liehl E, et al: Protection of mice from mortality caused by living and heat-killed bacteria by SDZ MRL 953. Circ Shock 1994; 42:121-127
21. Saiki I, Sato K, Yoo YC, et al: Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60). Int J Cancer 1992; 51:641-645
22. Zhu XF, Zhang XS, Li ZM, et al: Apoptosis induced by ceramide in hepatocellular carcinoma Bel7402 cells. Acta Pharmacol Sin 2000; 21:225-228
23. Kandil E, Zhang H, Schulze R, et al: Sophorolipids block lethal effects of septic shock. J Am Coll Surg 2003; 197(3S):S40-S41
24. Scholz C, Mehta S, Bisht K, et al: Bioactivity of extracellular glycolipids: Investigation of potential anti-cancer activity of sophorolipids and sophorolipid-derivatives. Proc Am Chem Soc Polymer Preprints 1998; 39: 168-169
25. Seung-Hak B, Sun XX, Lee YJ, et al: Mitigation of harmful algae blooms by sophorolipid. J Microbiol Biotechnol 2003; 13:651-659
26. Bisht KS, Gross RA, Kaplan DL: Enzyme-mediated regioselective acylations of sophorolipids. J Org Chem 1999; 64:780-789
27. Singh SK, Felse AP, Nunez A, et al: Regioselective enzyme-catalyzed synthesis of sophorolipid esters, amides, and multifunctional monomers. J Org Chem 2003; 68:5466-5477
28. Wu CH, Chen TL, Chen TG, et al: Nitric oxide modulates pro- and anti-inflammatory cytokines in lipopolysaccharide-activated macrophages. J Trauma 2003; 55:540-545
29. Razavi HM, Wang LF, Weicker S, et al: Pulmonary neutrophils infiltration in murine sepsis: Role of inducible nitric oxide synthetase. Am J Respir Crit Care Med 2004; April e-pub: 10.1164/rccm. 200306-846OC
30. Sharshar T, Annane D, de la Grandmaison GL, et al: The neuropathology of septic shock. Brain Pathol 2004; 14:21-33
31. Cesar de Oliveira P, Boer-Lima PA, Figueiredo JF, et al: Effect of nitric oxide synthase inhibition and saline administration on blood pressure and renal sodium handling during experimental sepsis in rats. Ren Fail 2003; 25:897-908
32. Bakker J, Grover R, McLuckie A, et al: Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004; 32:1-12
33. Sjakste N, Baumane L, Boucher JL, et al: Effects of gamma-butyrobetaine and mildronate on nitric oxide production in lipopolysaccharide-treated rats. Pharmacol Toxicol 2004; 94:46-50
34. Lopez A, Lorente JA, Steingrub J, et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30
35. Watson D, Grover R, Anzueto A, et al: Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004; 32:13-20
36. Otero-Anton E, Gonzalez-Quintela A, Lopez-Soto A, et al: Cecal ligation and puncture as a model of sepsis in the rat: Influence of the puncture size on mortality, bacteremia, endotoxemia and tumor necrosis factor alpha levels. Eur Surg Res 2001; 33:77-79
37. Dib M, Zhao X, Wang X, et al: Acute phase response in acute pancreatitis: A comparison with abdominal sepsis. Scand J Gastroenterol 2003; 38:1072-1077
38. Kang YJ, Seo SJ, Yun-Choi HS, et al: A synthetic isoquinoline alkaloid, 1-(beta-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (YS 51), reduces inducible nitric oxide synthase expression and improves survival in a rodent model of endotoxic shock. J Pharmacol Exp Ther 2002; 301:561-567
39. Akman HO, Zhang H, Siddiqui MA, et al: Response to hypoxia involves transforming growth factor-β2 and Smad proteins in human endothelial cells. Blood 2001; 98:3324-3331
40. Cannon CJ, Malone DL, Napolitano LM, et al: Reduction of IL-10 and nitric oxide synthesis by SR31747A (sigma ligand) in RAW murine macrophages. Surg Infect 2001; 2:267-272
41. Sundrani R, Easington CR, Mattoo A, et al: Nitric oxide synthase inhibition increases venular leukocyte rolling and adhesion in septic rats. Crit Care Med 2000; 28:2898-2903
42. Mendez CAA, Kramer KF, Salhab GA, et al: Tolerance to shock: An exploration of mechanism. Ann Surg 1999; 229:843-850
43. Mira JPA,. Cariou F, Grail C, et al: Association of TNF2, a TNF promoter polymorphism, with septic shock susceptibility and mortality. JAMA 1999; 282:561-568
44. Bone RC: Gram-negative sepsis: A dilemma of modern medicine. Clin Microbiol Rev 1993; 6:57-68
45. Zervos EJ, Norman D, Denham LC, et al: Cytokine activation through sublethal hemorrhage is protective against early lethal endotoxic challenge. Arch Surg 1997; 132:1216-1221
46. Prins JM, Kuijper EJ, Mevissen MCLM, et al: Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: Influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 1995; 63:2236-2242
47. Tracey KJ, Fong Y, Hesse D, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664
48. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999; 340:207-214
49. Bochud PY, Calandra T: Pathogenesis of sepsis: New concepts and implications for future treatment. BMJ 2003; 326:262-266
50. Lynn WA: Anti-endotoxin therapeutic options for the treatment of sepsis. J Antimicrob Chemother 1998; 41(suppl A):71-80
51. Cross AS, Opal S, Cook P, et al: Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis. Vaccine 2004; 22:812-817
52. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
53. Barie PS, Williams MD, McCollam JS, et al: Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004; 188:212-220
54. Ely EW, Laterre PF, Angus DC, et al: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31:12-19
55. Ikeda Y, Sunakawa T, Tsuchiya S, et al: Toxicological studies on sophorolipid derivatives: (I). Acute toxicity, eye irritation, primary skin irritation, skin sensitization, phototoxicity, photosensitization, mutagenicity of polyoxypropylene (12) [(2′-0-beta-D-glucopyranosyl-beta-D- glucopyranosyl)oxy-] fatty acid ester. J Toxicol Sci 1986; 11:197-211
56. Ikeda Y, Sunakawa T, Okamoto K, et al: Toxicological studies on sophorolipid derivatives: (II). Subacute toxicity study of polyoxypropylene (12) [2′-0-beta-D-glucopyranosyl-beta-D-glucopyranosyl) oxy-] fatty acid ester. J Toxicol Sci 1986; 11:213-224
57. Otto RT, Daniel HJ, Pekin G, et al: Production of sophorolipids from whey: II. Product composition surface active properties, cytotoxicity and stability against hydrolases by enzymatic treatment. Appl Microbiol Biotechnol 1999; 52:495-501
58. Awasthi A, Kumar A, Upadhyay SN, et al: Nitric oxide protects against chloroquine resistant Plasmodium yoelii nigeriensis parasites in vitro. Exp Parasitol 2003; 105:184-191
59. Voldoukis I, Riveros-Moreno V, Dugas B, et al: The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the FceRII/CD23e surface antigen. Proc Natl Acad Sci 1995; 92:7804-7808
60. Taylor RW, Zimmerman JL, Dellinger RP, et al: Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: A randomized controlled trial. JAMA 2004; 291:1603-1609
61. Bermejo A, Zarzuelo A, Duarte J: In vivo vascular effects of genistein on a rat model of septic shock induced by lipopolysaccharide. J Cardiovasc Pharmacol 2003; 42:329-338
62. Mikawa K, Nishina K, Takao Y, et al: ONO-1714, a nitric oxide synthase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits. Anesth Analg 2003; 97:1751-1755
63. James PE, Madhani M, Ross C, et al: Tissue hypoxia during bacterial sepsis is attenuated by PR-39, a antibacterial peptide. Adv Exp Med Biol 2003; 530:645-652
64. Ji B, Chen X, Misek DE, et al: Pancreatic gene expression during the initiation of acute pancreatitis: identification of EGR-1 as a key regulator. Physiol Genomics 2003; 14:59
65. Cannon JG, Tompkins RG, Gelfand JA, et al: Circulating interleukin I and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161:79-84
66. Karres I, Kremer JP, Steckholzer U, et al: TGF-β1 inhibits synthesis of cytokines in endotoxin-stimulated whole blood. Arch Surg 1996; 131:1310-1317
67. Marie C, Cavaillon JM, Losser MR: Elevated levels of circulating transforming growth factor-β1 in patients with the sepsis syndrome. Ann Intern Med 1996; 125:520-521
68. Junger WG, Hoyt DB, Redl H, et al: Tumor necrosis factor antibody treatment of septic baboons reduces the production of sustained T-cell suppressive factors. Shock 1995; 3:173-178
69. Okino T, Chakraborty NG, Ergin MT, et al: Suppressor function of lymphocytes activated in in vitro co-culture against autologous tumor cells and expanded in interleukin-2. In Vivo 1991; 5:631-635
70. Bodey B, Bodey B Jr, Siegel SE, et al: Significant differences in the matrix metalloproteinase expression profiles of spontaneous medulloblastomas/ primitive neuroectodermal tumors as compared with their xenografted, established tumor cell line derived counterparts. In Vivo 2000; 14:675-682
71. Lovgren TR, Tarantolo SR, Evans C, et al: Enhanced in vitro and in vivo cytotoxicity of umbilical cord blood cells against human breast cancer following activation with IL-15 and colony stimulating factors. In Vivo 2002; 16:541-550